PubMed

Effects of 3 months of continuous subcutaneous administration of glucagon-like peptide 1 in elderly patients with type 2 diabetes.

Meneilly GS, Greig N, Tildesley H, Habener JF, Egan JM, Elahi D.

Diabetes Care. 2003 Oct;26(10):2835-41.PMID: 14514588 [PubMed - indexed for MEDLINE]Related articlesFree article

Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

Toft-Nielsen MB, Madsbad S, Holst JJ.

Diabetes Care. 1999 Jul;22(7):1137-43.PMID: 10388979 [PubMed - indexed for MEDLINE]Related articlesFree article

No hypoglycemia after subcutaneous administration of glucagon-like peptide-1 in lean type 2 diabetic patients and in patients with diabetes secondary to chronic pancreatitis.

Knop FK, Vilsbøll T, Larsen S, Madsbad S, Holst JJ, Krarup T.

Diabetes Care. 2003 Sep;26(9):2581-7.PMID: 12941722 [PubMed - indexed for MEDLINE]Related articlesFree article

Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure.

Nauck MA, Sauerwald A, Ritzel R, Holst JJ, Schmiegel W.

Diabetes Care. 1998 Nov;21(11):1925-31.PMID: 9802745 [PubMed - indexed for MEDLINE]Related articlesFree article

Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state.

Egan JM, Meneilly GS, Habener JF, Elahi D.

J Clin Endocrinol Metab. 2002 Aug;87(8):3768-73.PMID: 12161508 [PubMed - indexed for MEDLINE]Related articlesFree article

Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment.

Larsen J, Hylleberg B, Ng K, Damsbo P.

Diabetes Care. 2001 Aug;24(8):1416-21.PMID: 11473079 [PubMed - indexed for MEDLINE]Related articlesFree article

Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients.

Nauck MA, Weber I, Bach I, Richter S, Orskov C, Holst JJ, Schmiegel W.

Diabet Med. 1998 Nov;15(11):937-45.PMID: 9827848 [PubMed - indexed for MEDLINE]Related articles

Additive effects of glucagon-like peptide 1 and pioglitazone in patients with type 2 diabetes.

Zander M, Christiansen A, Madsbad S, Holst JJ.

Diabetes Care. 2004 Aug;27(8):1910-4.PMID: 15277416 [PubMed - indexed for MEDLINE]Related articlesFree article

Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.

Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA.

Diabetes Care. 1996 Jun;19(6):580-6.PMID: 8725855 [PubMed - indexed for MEDLINE]Related articles

Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans.

Quddusi S, Vahl TP, Hanson K, Prigeon RL, D'Alessio DA.

Diabetes Care. 2003 Mar;26(3):791-8.PMID: 12610039 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.

Nauck MA, Wollschläger D, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Willms B.

Diabetologia. 1996 Dec;39(12):1546-53.PMID: 8960841 [PubMed - indexed for MEDLINE]Related articles

Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM.

Rachman J, Barrow BA, Levy JC, Turner RC.

Diabetologia. 1997 Feb;40(2):205-11.PMID: 9049482 [PubMed - indexed for MEDLINE]Related articles

No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose.

Vilsbøll T, Krarup T, Madsbad S, Holst JJ.

Diabet Med. 2001 Feb;18(2):144-9.PMID: 11251679 [PubMed - indexed for MEDLINE]Related articles

Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes.

Toft-Nielsen MB, Madsbad S, Holst JJ.

J Clin Endocrinol Metab. 2001 Aug;86(8):3853-60.PMID: 11502823 [PubMed - indexed for MEDLINE]Related articlesFree article

Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.

Vilsbøll T, Krarup T, Madsbad S, Holst JJ.

Diabetologia. 2002 Aug;45(8):1111-9. Epub 2002 Jul 4.PMID: 12189441 [PubMed - indexed for MEDLINE]Related articles

Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes.

Zander M, Taskiran M, Toft-Nielsen MB, Madsbad S, Holst JJ.

Diabetes Care. 2001 Apr;24(4):720-5.PMID: 11315837 [PubMed - indexed for MEDLINE]Related articlesFree article

Glucagon-like peptide-1 (7-37) augments insulin-mediated glucose uptake in elderly patients with diabetes.

Meneilly GS, McIntosh CH, Pederson RA, Habener JF, Gingerich R, Egan JM, Elahi D.

J Gerontol A Biol Sci Med Sci. 2001 Nov;56(11):M681-5.PMID: 11682575 [PubMed - indexed for MEDLINE]Related articles

Overnight GLP-1 normalizes fasting but not daytime plasma glucose levels in NIDDM patients.

Willms B, Idowu K, Holst JJ, Creutzfeldt W, Nauck MA.

Exp Clin Endocrinol Diabetes. 1998;106(2):103-7.PMID: 9628239 [PubMed - indexed for MEDLINE]Related articles

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study.

Zander M, Madsbad S, Madsen JL, Holst JJ.

Lancet. 2002 Mar 9;359(9309):824-30.PMID: 11897280 [PubMed - indexed for MEDLINE]Related articles

Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes.

Todd JF, Edwards CM, Ghatei MA, Mather HM, Bloom SR.

Clin Sci (Lond). 1998 Sep;95(3):325-9.PMID: 9730852 [PubMed - indexed for MEDLINE]Related articles